Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
NEW BRUNSWICK, N.J., DECEMBER 5, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match...
Source: Johnson and Johnson - December 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 vaccination and rare side effects including blood clotting, SPS (published 26th November 2021)
This resource provides information about rare side effects associated with COVID-19 vaccination focussing on blood clotting, myocarditis and Guillain-Barre syndrome. Incidence and vaccines implicated, and age specific advice as well as management strategies are included. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 30, 2021 Category: Consumer Health News Source Type: news

COVID-19 vaccination and rare side effects, UK Health Security Agency (updated 29th November 2021)
Guidance relating to blood clotting, myocarditis and Guillain-Barr é Syndrome (GBS) after COVID-19 vaccination. 29 November 2021Added myocarditis and pericarditis after COVID-19 vaccination guidance. 18 August 2021First published. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 29, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant
Since the emergence of the COVID-19 pandemic, Johnson & Johnson (the Company) has been closely monitoring newly emerging COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the Company has been evaluating the effectiveness of its COVID-19 vaccine across variants, including now the new and rapidly spreading Omicron variant. The Company is testing blood serum from participants in completed and ongoing booster studies to look for neutralizing activity against the Omicron variant. In addition, the Company is pursuing an Omicron-specific variant vaccine and will progress it as need...
Source: Johnson and Johnson - November 29, 2021 Category: Pharmaceuticals Source Type: news

COVID-19: the green book, chapter 14a, UK Health Security Agency (updated 15th November 2021)
Coronavirus (COVID-19) vaccination information for public health professionals. 15 November 2021Updated to include second doses for 16 to 17 year olds and booster doses for 40 to 49 year olds; further clarification on booster timing flexibility; guidance on deferral after COVID-19 infection in under 18s and other minor edits for clarification. 29 October 2021Updated to improve consistency of wording in the allergy and immunosuppressed sections; updated definitions of clinically vulnerable, advice on further doses for those who have suspected myocarditis or Guillain-Barr é Syndrome after vaccination, clarifying f...
Source: Current Awareness Service for Health (CASH) - November 16, 2021 Category: Consumer Health News Source Type: news

Study: Shingrix shingles vaccine riskier for Guillain-Barr é than older shot
Older adults who receive the Shingrix shingles vaccines are more than twice as likely to develop Guillain-Barr é syndrome compared with those given the older Zostavax product, a JAMA Internal Medicine study found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 1, 2021 Category: Consumer Health News Source Type: news

Update to COVID-19 chapter of the green book (chapter 14a), UK Health Security Agency (updated 29th October 2021)
Coronavirus (COVID-19) vaccination information for public health professionals. 29 October 2021Updated to improve consistency of wording in the allergy and immunosuppressed sections; updated definitions of clinically vulnerable, advice on further doses for those who have suspected myocarditis or Guillain-Barr é Syndrome after vaccination, clarifying flexibility around the booster timing and supply, additional evidence on booster dose effectiveness and on vaccination after monoclonal antibody products. 16 September 2021Updated to include new recommendations on boosters and children and young people. Minor updates...
Source: Current Awareness Service for Health (CASH) - November 1, 2021 Category: Consumer Health News Source Type: news

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection, Nature Medicine
Analysis of self-controlled case series notes although there was increased risk of neurological complications in those who received COVID-19 vaccines, risk is greater following positive SARS-CoV-2 test (38 vs. 145 excess cases of Guillain –Barr é syndrome/10 million, respectively). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 27, 2021 Category: Consumer Health News Source Type: news

Covid: Vaccine study links virus to rare neurological illness
Guillain-Barre Syndrome is more likely to occur in people who catch Covid, study finds. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 25, 2021 Category: Consumer Health News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
NEW BRUNSWICK, N.J., October 21, 2021 – Johnson & Johnson (the Company) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine. “Today’s recommendation supports the use of the Johnson & Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientif...
Source: Johnson and Johnson - October 21, 2021 Category: Pharmaceuticals Source Type: news

CDC Authorizes Boosters of Moderna and Johnson & Johnson COVID-19 Vaccines
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day. The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and ...
Source: TIME: Health - October 21, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

CDC Authorizes Boosters of Moderna and Johnson & Johnson COVID-19 Vaccines
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day. The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and ...
Source: TIME: Health - October 21, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
NEW BRUNSWICK, N.J., October 20, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recomme...
Source: Johnson and Johnson - October 20, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., October 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. The vote was based on findings from two Company clinical trials, including the Phase 3 ENSEMBLE 2 study, which evaluated a booster dose of the Johnson &...
Source: Johnson and Johnson - October 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pandemic Data Challenges Infection Link to Guillain-Barr é Pandemic Data Challenges Infection Link to Guillain-Barr é
Armed with data from the COVID-19 pandemic, researchers are suggesting that most cases of Guillain-Barr é syndrome are not connected to infectious disease after all.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 13, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., October 05, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a booster shot of the Johnson & Johnson COVID-19 vaccine in individuals 18 years of age and older.The submission includes recent results from the Phase 3 ENSEMBLE 2 study that found a booster of the Johnson & Johnson COVID-19 vaccine given 56 days after the primary dose provided 94 percent protection against symptomatic (moderate to severe/critical) COVID-19 in the U.S. (CI, 58%-100%) and 100 percent protection (CI, 33%-100%) a...
Source: Johnson and Johnson - October 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Guillain - Barr é Syndrome May Be Triggered by SARS - CoV - 2 Infection
During study period, 22 percent with GBS had confirmed or probable SARS - CoV - 2 infection; patients had uniform neurologic features (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 25, 2021 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Emergency Medicine, Neurology, Pulmonology, Journal, Source Type: news

COVID-19 could make Guillain-Barre more likely for people at risk for disorder
People with COVID-19 may be at increased risk for developing Guillain-Barre syndrome, a study published Friday by the journal Brain found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 24, 2021 Category: Consumer Health News Source Type: news

COVID-19 a Rare Trigger for Guillain-Barr é Syndrome COVID-19 a Rare Trigger for Guillain-Barr é Syndrome
COVID-19 may precede Guillain-Barr é syndrome in rare cases, but a strong link is not likely, according to new data from an international consortium.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 23, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news

Covid may be an occasional trigger of rare Guillain-Barré syndrome
Research of Guillain-Barré syndrome patients in China, France, Greece, Italy, the Netherlands, Spain, Switzerland, and the UK suggests there is a correlation between Covid infection and the condition. (Source: the Mail online | Health)
Source: the Mail online | Health - September 23, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety,...
Source: Johnson and Johnson - September 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Nerve disorder listed as 'very rare' side effect of AstraZeneca jab
Guillain-Barre Syndrome is a "very rare" side effect, occurring in under one in 10,000 people. The disorder is a nerve inflammation that may cause temporary paralysis and difficulty breathing. (Source: The Economic Times)
Source: The Economic Times - September 10, 2021 Category: Consumer Health News Source Type: news

AstraZeneca's Covid jab can trigger nerve disorder Guillain-Barre syndrome, EU says
The European Medicines Agency said they considered it to be 'at least a reasonable possibility' that the AstraZeneca jab could trigger the condition in 'very rare' cases. (Source: the Mail online | Health)
Source: the Mail online | Health - September 9, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Information for healthcare professionals on Guillain-Barr é Syndrome (GBS) following COVID-19 vaccination, PHE (published 20th August 2021)
Guidance includes information on presentation/symptoms of GBS, current UK data and reporting suspected cases following COVID vaccination and how to manage patients with previous history. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 24, 2021 Category: Consumer Health News Source Type: news

Coronavirus disease 2019 (COVID-19) Updates, BMJ Best Practice
1. NICE publishes new guidance on vaccine-induced immune thrombocytopenia and thrombosis. 2. FDA authorises casirivimab/imdevimab for prevention of COVID-19. 3. EMA warns of Guillain-Barre syndrome with Janssen COVID-19 vaccine. 4. EMA authorises use of Moderna COVID-19 vaccine in young people aged 12 to 17 years. 5. CDC warns that vaccinated people with breakthrough infections can spread the Delta variant. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news

European PRAC continues review reports of Guillain-Barr é syndrome with Astra Zeneca (Vaxzevria) COVID-19 vaccine, EMA
PRAC continues to analyse data on cases of Guillain-Barr é syndrome following vaccination and has requested the marketing authorisation holder to clarify whether further updates to the product information and the risk management plan are necessary. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 10, 2021 Category: Consumer Health News Source Type: news

COVID-19 Vaccine Janssen: Guillain-Barr é syndrome (GBS) listed as a very rare side effect, EMA
The European PRAC has assessed the available information (108 cases reported worldwide, when over 21 million had received the vaccine) and concluded that a causal relationship between Covid-19 Vaccine Janssen and the neurological disorder GBS is possible. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 26, 2021 Category: Consumer Health News Source Type: news

CDC Panel Updates Info on Rare Side Effect After J & J Vaccine CDC Panel Updates Info on Rare Side Effect After J & J Vaccine
The ACIP discussed slightly higher rates of the rare side effect of Guillain-Barr é syndrome after the J&J vaccine, and presented reaffirming evidence of the vaccine's effectiveness against variants.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 23, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

J & J vaccine and Guillain-Barr é syndrome: Information on the FDA warning
Regulators and Yale experts say the benefits of receiving the vaccine still outweigh the risks, citing the rare chance of developing the neurological disorder. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 21, 2021 Category: Universities & Medical Training Source Type: news

What You Need to Know About COVID-19 Booster Shots
Since the U.S. began a massive country-wide vaccination effort against COVID-19 last winter, a majority of adult Americans have been immunized. But now it seems that all of them may need an additional dose next year. Public health experts including Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, stress that studies continue to show that the three vaccines currently authorized in the U.S. protect against COVID-19 disease, including against variants of the virus that are more transmissible. But as effective as the vaccines are, they can’t provide 100% immunity against disease. ...
Source: TIME: Health - July 15, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., July 14, 2021 – Interim results from a Phase 1/2a sub-study published in the New England Journal of Medicine (NEJM) demonstrated that both humoral (antibody) and cellular (T-cell) immune responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization, the length of time evaluated to date. Data showed that T-cell responses – including the important CD8+ T-cells that seek out and destroy infected cells – persisted over the eight-month timeframe examined. The Company announced topline preprint study results from...
Source: Johnson and Johnson - July 14, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 July 2021, EMA
The PRAC has recommended a change to the product information for Vaxzevria (formerly COVID 19 Vaccine Astrazeneca) to include a warning to raise awareness among healthcare professionals and people taking the vaccine of cases of Guillain-Barre syndrome (GBS) reported following vaccination. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 14, 2021 Category: Consumer Health News Source Type: news

FDA Warns J & J Vaccine Can Increase Guillain-Barre
FDA to Warn J&J Vaccine Can Increase Guillain-Barre Risk (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 14, 2021 Category: General Medicine Source Type: news

FDA Warns About J & J COVID Vaccine and Guillain-Barr é Syndrome Risk
The first symptom of the disorder is usually a weakness or tingling sensation in both legs. (Source: Reuters: Health)
Source: Reuters: Health - July 13, 2021 Category: Consumer Health News Source Type: news

What is Guillain-Barré syndrome? FDA warns of ‘Increased risk’ after vaccine
GUILLAIN-BARR É syndrome has been linked to the Covid vaccine after US authorities warned the Johnson& Johnson jab may be related to the rare syndrome. But what is Guillain-Barr é syndrome? (Source: Daily Express - Health)
Source: Daily Express - Health - July 13, 2021 Category: Consumer Health News Source Type: news

The FDA ’s New Guillain-Barre Warning For the J & J Vaccine Reflects a Small Increased Risk of the Illness
As millions of people get vaccinated against COVID-19, the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are closely monitoring reports of side effects and adverse events among people getting immunized. On July 12, the FDA added a warning about the risk of Guillain-Barre to the single-dose Janssen/Johnson & Johnson vaccine. Anyone who receives the shot moving forward will get an updated fact sheet informing them of the small but increased risk. There have not been significant reports of the syndrome linked to the two other vaccines authorized in the U.S., made by Pfize...
Source: TIME: Health - July 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

FDA adds warning to J & J COVID-19 vaccine over links to rare autoimmune disorder
The U.S. Food and Drug Administration announced a new warning for the Johnson& Johnson COVID-19 vaccine over its association with an increased risk of Guillain-Barre syndrome. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 13, 2021 Category: Consumer Health News Source Type: news

Guillain-Barr é Syndrome and the Johnson & Johnson Vaccine: What to Know
The link between the rare neurological disorder and the Johnson& Johnson Covid-19 vaccine may be real, but the risk appears to be very small. (Source: NYT Health)
Source: NYT Health - July 13, 2021 Category: Consumer Health News Authors: Emily Anthes Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Guillain-Barre Syndrome Centers for Disease Control and Prevention Food and Drug Administration Johnson & your-feed-health your-feed-science Source Type: news

FDA to Warn J & J Vaccine Can Increase Guillain-Barr é Risk: Media FDA to Warn J & J Vaccine Can Increase Guillain-Barr é Risk: Media
The federal agency is acting after receiving more than 100 reports of rare Guillain-Barr é syndrome linked to receipt of the J&J vaccines.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 13, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Covid Vaccine
Federal regulators concluded that the risk of developing the syndrome was low, and that the benefits of the vaccine still strongly outweigh it. (Source: NYT Health)
Source: NYT Health - July 13, 2021 Category: Consumer Health News Authors: Sharon LaFraniere and Noah Weiland Tags: Johnson & Guillain-Barre Syndrome Vaccination and Immunization Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Disease Rates Regulation and Deregulation of Industry Food and Drug Administration Centers for Disease Control and Prevention Source Type: news

FDA Adds Guillain-Barr é Warning to J & J COVID-19 Vaccine
MONDAY, July 12, 2021 -- The U.S. Food and Drug Administration issued a new warning for the Johnson& Johnson COVID-19 vaccine that says the shot has been tied to Guillain-Barr é syndrome. Officials said there is a " small possible risk " for the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2021 Category: Pharmaceuticals Source Type: news

FDA adds new warning on Johnson & Johnson vaccine related to rare autoimmune disorder
About 100 preliminary reports of Guillain-Barré have been detected after 12.8 million doses of Johnson & Johnson vaccine were administered, the Centers for Disease Control and Prevention said in a statement. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - July 12, 2021 Category: Consumer Health News Authors: Laurie McGinley Source Type: news

What To Know About The Johnson & Johnson COVID Vaccine And Guillain-Barre Syndrome
The FDA added a warning on the J&J shot after some people developed a rare disorder. Here's why you shouldn't panic. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - July 12, 2021 Category: Science Source Type: news

What To Know About The J&J COVID Vaccine And Guillain-Barre Syndrome
The FDA added a warning on the J&J shot after some people developed a rare disorder. Here's why you shouldn't panic. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - July 12, 2021 Category: Consumer Health News Source Type: news

J&J COVID vaccine may pose 'small possible risk' of rare neurological syndrome, CDC says
The U.S. Centers for Disease Control and Prevention said on Monday that it has received rare reports of Guillain-Barré syndrome among people who got Johnson & Johnson's Janssen shot. The vaccine has been approved in Canada but never used. (Source: CBC | Health)
Source: CBC | Health - July 12, 2021 Category: Consumer Health News Tags: News/Health Source Type: news

Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
NEW BRUNSWICK, N.J., July 12, 2021 – The safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its COVID-19 Vaccine Factsheet to include important information about these rare cases and on the signs and symptoms of Guillain-Barré syndrome. Updates with this new information will be implemented in other regions...
Source: Johnson and Johnson - July 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Case Reports Identify Guillain-Barr é Variants After COVID Vaccine Case Reports Identify Guillain-Barr é Variants After COVID Vaccine
Report findings from India and the UK'should prompt all physicians to be vigilant in recognizing Guillain-Barr é syndrome in patients who have received the AstraZeneca vaccine,'investigators say.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - July 1, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news

Seven Cases of Guillain-Barr é Noted After COVID-19 Vaccine in India
MONDAY, June 28, 2021 -- Cases of Guillain-Barr é syndrome (GBS) have been reported after receipt of the Oxford-AstraZeneca severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, according to two reports published online June 10 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 28, 2021 Category: Pharmaceuticals Source Type: news